SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare soars as its arm gets CEP from EDQM for API Octreotide

19 Nov 2024 Evaluate

Shilpa Medicare is currently trading at Rs. 896.50, up by 33.10 points or 3.83% from its previous closing of Rs. 863.40 on the BSE.

The scrip opened at Rs. 885.40 and has touched a high and low of Rs. 917.20 and Rs. 881.60 respectively. So far 23504 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 959.95 on 18-Sep-2024 and a 52 week low of Rs. 313.55 on 10-Jan-2024.

Last one week high and low of the scrip stood at Rs. 917.20 and Rs. 814.00 respectively. The current market cap of the company is Rs. 8714.64 crore.

The promoters holding in the company stood at 44.33%, while Institutions and Non-Institutions held 17.76% and 37.90% respectively.

Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Octreotide.

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.

Octreotide is second peptide molecule in Shilpa’ s peptide portfolio. The CEP showcases its expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×